Alpha D3-Teva

Alpha D3-Teva – the drug regulating exchange of phosphorus and calcium in an organism.

Form of release and structure

Medicine is produced in capsules a dosage of 1, 0,5 and 0,25 mkg. The main operating component – альфакальцидол.

Excipients: propyl gallate, peanut butter, anhydrous citric acid, anhydrous ethanol, tocopherol.

Structure of gelatin capsules: глицерол, gelatin, red iron oxide (E172), titanium dioxide (E171), yellow iron oxide (E172), анидрисорб 85/70.

Indications to use

According to the instruction, Alpha D3-Teva appoint at:

• Osteodystrophies at a renal failure in a chronic form;
• Osteoporosis, including senile, postmenopauzny, steroid;
• Hypoparathyrosis and pseudohypoparathyroidism;
• Pseudo-scarce (vitamin D-dependent) rickets and osteomalacy;
• Gipofosfatemichesk (vitamin D-resistant) rickets and osteomalacy;
• Renal acidosis;
• Fankoni's syndrome (hereditary renal acidosis with a nephrocalcinosis, an adiposagenital syndrome and late rickets).

Contraindications

According to the instruction, Alpha D3-Teva it is contraindicated at:

• Hypervitaminosis D;
• Gipermagniyemiya;
• Hyperphosphatemias (an exception the hyperphosphatemia at a hypoparathyrosis makes);
• Hypercalcemias;
• Feeding by a breast;
• Hypersensitivity to drug components.

With care appoint Alpha D3-Teva to patients with a heart and renal failure, atherosclerosis, a nephrolithiasis, a sarcoidosis, an active form of a pulmonary tuberculosis, and also to patients with predisposition to a hypercalcemia, in particular, at an urolithiasis.

Administration of drug during pregnancy is appointed only if the possible advantage of treatment of mother exceeds risk for a fruit. The hypercalcemia during pregnancy can cause defects of fetation.

Route of administration and dosage

To adults and children 3 years at the rickets and osteomalacy caused by insufficiency of food are more senior appoint drug in a dose of 1-3 mkg a day.

The daily dose for adults at a hypoparathyrosis makes 1-4 mkg.

At gipofosfatemichesky rickets and osteomalacy drug appoint in an initial dosage 4 mkg a day which can be gradually raised to 20 mkg a day. To children 3 years a course of treatment are more senior begin with 1 mkg a day.

At an osteodystrophy with a renal failure in a chronic form the adult appoint Alpha D3-Teva 0,5-2 mkg, to children 3 years – on 0,5-1 mkg a day are more senior.

At senile, steroid, postmenopauzny osteoporosis drug is appointed in number of 0,5-1 mkg a day.

At renal acidosis and Fankoni's syndrome the dosage for adults and children is more senior than 3 years makes 2-6 mkg a day.

Use Alpha D3-Teva is begun with the minimum specified doses, once a week controlling the level of phosphorus and calcium in a blood plasma. Increase in a dosage of drug on 0,25-0,5 mkg a day up to stabilization of biochemical indicators is allowed. On reaching a minimal effective dose it is recommended to carry out control of phosphorus and calcium in a blood plasma at least once a month.

Duration of a course is determined by the attending physician individually depending on the course of a disease and efficiency of therapy.

Side effects

Use Alpha D3-Teva can cause the following side effects:

• From system of digestion: an abdominal pain, anorexia, vomiting, heartburn, dryness in a mouth, nausea, a lock or diarrhea, a sensation of discomfort in the field of an epigastrium. Seldom – slight increase of nuclear heating plant, ALT in a blood plasma;
• From a metabolism: seldom – a hypercalcemia, it is very rare – insignificant increase in LPVP in plasma, a hyperphosphatemia;
• From cardiovascular system: tachycardia;
• From the central nervous system: weakness, headache, fatigue, drowsiness and dizziness;
• Allergic reactions: skin itch and rash.

According to the instruction, Alpha D3-Teva in case of overdose can cause the following phenomena:

• Early symptomatology of a hypervitaminosis D: a lock or diarrhea, vomiting, nausea, anorexia, dryness in a mouth, headaches, metal smack in a mouth, bystry fatigue, a polydipsia, a polyuria, a hypercalcuria, a pollakiuria/nocturia, a mialgiya, the general weakness, ostealgias;
• Late symptomatology of a hypervitaminosis D: drowsiness, confusion of consciousness, dizziness, increase in arterial pressure, disturbance of a heart rhythm, urine opacification, nephrolithiasis, conjunctiva hyperemia, pancreatitis, weight reduction, gastralgia, photophobia;
• Chronic symptomatology of a hypervitaminosis D: calcification of blood vessels, soft tissues, lungs and kidneys, a cardiovascular and renal failure with a possible lethal outcome.

At emergence of these symptoms it is necessary to stop administration of drug. To avoid overdose by medicine, it is necessary to carry out regular inspections of functions of heart and kidneys during a course of treatment, and also to control the content in blood of electrolytes.

Special instructions

At treatment of osteoporosis appointment Alpha D3-Teva together with the medicines reducing a bone resorption and estrogen is possible.

The concomitant use of an alfakaltsidol with cardiac glycosides can cause disturbances of a cordial rhythm.

At combined use of medicine with mineral oil, kolestipoly, Colestyraminum, antacids, sukralfaty and other drugs on the basis of albumine, its absorbability decreases.

Simultaneous use with thiazide diuretics, calcium drugs, vitamin D increases risk of emergence of a hypercalcemia.

Alpha D3-Teva can cause dizziness and drowsiness therefore for the period of a course of treatment it is necessary to observe the increased care at management of transport and work with difficult mechanisms.

Analogs

Medicines Etalfa and Alfadol belong to structural analogs Alpha D3-Teva.

Conditions and periods of storage

Drug should be stored in the place protected from impact of a sunlight at air temperature not above 25 °C.

Period of validity - 3 years of date of production.